Metabolic Phenotypes: Drivers of Health Outcomes in Fatty Liver Diseases.

IF 3.1 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Journal of Clinical and Translational Hepatology Pub Date : 2023-08-28 DOI:10.14218/JCTH.2022.00170S

Phunchai Charatcharoenwitthaya

引用次数: 0

Abstract

(

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

代谢表型:脂肪肝疾病健康结果的驱动因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Clinical and Translational Hepatology GASTROENTEROLOGY & HEPATOLOGY-

CiteScore

6.40

自引率

2.80%

发文量

496

期刊最新文献

Chinese Clinical Practice Guidelines for the Prevention and Treatment of Mother-to-child Transmission of Hepatitis B Virus (Version 2024). A Case of Severe Cholestatic Hepatitis Induced by a Novel Dual Agonist of Glucagon-like Peptide-1 and Glucose-dependent Insulinotropic Polypeptide Receptors. GPX4 Promoter Hypermethylation Induced by Ischemia/Reperfusion Injury Regulates Hepatocytic Ferroptosis. Guideline for the Prevention and Treatment of Metabolic Dysfunction-associated Fatty Liver Disease (Version 2024). Identification and Validation of the Hsa_circ_0001726/miR-140-3p/KRAS Axis in Hepatocellular Carcinoma Based on Microarray Analyses and Experiments.